-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Before the advent of anti-HER2 therapies, patients with HER2-positive breast cancer had a poor prognosis
.
The clinical application of the first anti-HER2 drug trastuzumab has significantly improved the prognosis of patients with HER2-positive breast cancer
Before the advent of anti-HER2 therapies, patients with HER2-positive breast cancer had a poor prognosis
Research and search the PubMed, EMBASE, and Web of Science databases until August 2020
.
Randomized clinical studies comparing the efficacy and safety of different anti-HER2 regimens in patients with metastatic HER2-positive (≤second-line treatment) prior trastuzumab (Tra) and taxane in the treatment of advanced breast cancer were included
Research and search the PubMed, EMBASE, and Web of Science databases until August 2020
The study finally included 12 studies with a total of 4353 patients
All 12 studies reported progression-free survival (PFS) results
PFS comparison of different schemes
PFS comparison of different schemesAll 10 studies reported overall survival (OS) results
.
For overall survival (OS), Pyr-Cap is better than Lap-Cap (HR=0.
All 10 studies reported overall survival (OS) results
Comparison of different schemes of OS
Comparison of different schemes of OSAll 10 studies reported ORR results
.
For ORR, Pyr-Cap is better than Cap (ORR=7.
All 10 studies reported ORR results
There was no statistically significant difference between treatment strategies for ≥ grade 3 adverse events
In summary , studies suggest that pyrrotinib is more effective than T-DM1 in the treatment of patients with metastatic HER-2 positive breast cancer, but the occurrence of ≥3 grade adverse events is also higher
Original source:
Liao H, Huang W, Liu Y, Pei W, Li H.
Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
Front Oncol.
2021 May 3;11:608781.
doi: 10.
3389/fonc.
2021.
608781.
PMID: 34012912; PMCID: PMC8127838.
Efficacy and Safety of Pyrotinib Versus T-DM1 in HER2+ Metastatic Breast Cancer Patients Pre-Treated With Trastuzumab and a Taxane: A Bayesian Network Meta-Analysis.
Front Oncol.
2021 May 3;11:608781.
doi: 10.
3389/fonc.
2021.
608781.
PMID: 34012912; PMCID: PMC8127838.
Leave a message here